Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy**The sponsor provided the principal investigator with the results of study AI 424-008 before the study's subsequent publication but did not participate in the data analysis presented in this report. A draft of the manuscript was submitted to the sponsor before submission with the understanding that the final manuscript remained under the complete control of the principal investigator.
Authors:
- Steven A. GroverSGSteven A. Grover
- Louis CoupalLCLouis Coupal
- Norbert GilmoreNGNorbert Gilmore
- Jayanti MukherjeeJMJayanti Mukherjee
- 1 March 2005
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 95 (5) , 586-591
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjectsAIDS, 2003
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Severe premature coronary artery disease with protease inhibitorsThe Lancet, 1998
- Estimating the Benefits of Modifying Risk Factors of Cardiovascular DiseaseArchives of internal medicine (1960), 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- An updated coronary risk profile. A statement for health professionals.Circulation, 1991
- Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with HypercholesterolemiaNew England Journal of Medicine, 1990
- Primary Prevention With Metoprolol in Patients With HypertensionJAMA, 1988
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study.Circulation, 1980